Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
|Articles|April 5, 2023
Exploring Automation and Sustainability with Nathan Pettus (Emerson Automation Exchange)
Author(s)Grant Playter
Nathan Pettus, president of Process Systems and Solutions at Emerson, discusses how automation is impacting recent sustainability technologies and solutions.
Advertisement
Nathan Pettus, president of Process Systems and Solutions at Emerson, discusses how automation is impacting recent sustainability technologies and solutions. Topics of discussion, among others, include:
- Recent Emerson sustainability initatives and the intersection between automation and sustainability in life sciences.
- Emerson's partnership with AspenTech and the advent of "one-click transfer technology.
- Underlooked technologies and innovations.
For more from the Emerson Automation exchange interview series, check
Advertisement
Related to this article
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
All 9 patients treated with BB-301 gene therapy met formal response criteria for improved swallowing in an ongoing OPMD trial.
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.
Izalontamab brengitecan extended median progression-free survival to 11.1 months vs 5.7 months with chemotherapy after EGFR TKI failure.
Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team cuts monoclonal antibody costs without cutting purification steps, and why the $10-per-gram target could make antibodies viable for infectious disease and global access.
Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team is making antibody manufacturing more efficient and replacing costly raw materials to cut monoclonal antibody costs to about $10 per gram.
Advertisement
Advertisement
Trending on BioPharm International
1
Adalvo Acquires Enzene’s Romiplostim Biosimilar Program for ITP
2
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
3
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
4
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
5